New: OMG Experience Expands European Air Freight Routes — New direct services to Zurich, Lisbon, and Warsaw Read more →
When drying, trimming, and curing trigger EU-GMP and Annex 7 herbal rules—not agriculture alone—and how Thai post-harvest facilities should design validation, change control, and batch records for EU inspectors.
In the European regulatory framing, medical cannabis may be classified as an API (active pharmaceutical ingredient), a herbal drug substance, or a finished herbal medicinal product depending on form and claims. EU-GMP and Annex 7 (herbal substances and herbal preparations) matter because many post-harvest steps—drying, trimming, curing, sieving, blending, and packaging—can be interpreted as the start of manufacturing, not “agriculture extended.” Thai operators who assume farm exemptions cover the entire facility often discover, mid-audit, that EU inspectors classify rooms and equipment as GMP areas requiring validation, cleaning verification, and batch records.
Disclaimer: Classification is fact-specific. Your importer, QP, and national competent authority determine how your operations map to GMP—this article frames common diligence questions, not a legal determination.
The decisive question is usually whether you perform defined processing that changes purity, homogeneity, or presentation in a controlled way intended for medicinal use. Drying to a target water activity with environmental monitoring looks like manufacturing. Casual barn drying with no alarms looks like risk. European customers are not snobs about buildings—they are assessing repeatability and contamination control.
For each step, ask: If we skip validation here, can we still defend batch uniformity and contamination control? If the honest answer is no, plan for GMP.
Validated rooms and equipment mean IQ/OQ/PQ or equivalent documented evidence that airflow, humidity, temperature, and equipment speed achieve approved ranges for each SKU. Change control applies when you swap dehumidifiers, re-route ductwork, or add a second shift—because those changes can alter bioburden and cross-contamination risk.
Microbial controls must be proportionate to the dosage form you claim. Inhalation or immunocompromised patient narratives drive stricter expectations than some oral herbal presentations—confirm with your importer’s QP.
Batch documentation should read like EU inspector expectations: clear in-process controls, yield reconciliation, label reconciliation, and deviation management.
Create a matrix listing each unit operation (receive harvest, dry, trim, blend, pack), its inputs, outputs, critical parameters, monitoring method, and release criteria. That matrix becomes the skeleton of your master batch record and your customer’s technical agreement schedules.
| Step | Critical parameter | Range | Monitor | Record location |
|---|---|---|---|---|
| Drying | Bed depth | X–Y cm | SOP + photo standard | Batch record §3 |
| Drying | Exhaust RH | ≤ N% | Sensor log | Annex D |
Uncalibrated balances, ad-hoc blending without homogeneity studies, wooden pallets in clean corridors, and unclear waste pathways for THC-containing trim. Long-form SOPs with photos reduce interpretation drift between shifts.
Validation proves a defined method works for worst-case soil. Verification is ongoing swabbing after known campaigns. EU sites get written up when only visual clean is claimed without data.
Treat equipment arrival as a project: URS (user requirements), DQ/IQ/OQ/PQ packages, training, and maintenance plans before GMP use. Using equipment “just for trials” without documentation creates unofficial GMP history that auditors will still ask about.
Your technical/quality agreement with the EU partner should spell out who owns each validation report, raw data retention, and change notification timelines. Ambiguity here causes months of email tennis after first OOS investigation.
Often yes if material is destined for EU medicinal channels. The exact room grading depends on product classification and company policy agreed with the importer.
Yes, with physical separation, air pressure cascades, personnel flows, and material flows that prevent dirty-to-clean backtracking. Document zoning in your site diagram.
Major repairs, new equipment, process limit changes, and recurring deviations. Maintain a validation master plan even if it starts as a 10-page internal standard.
Annex 7 expectations reinforce identity, purity, and control of foreign matter for herbal substances—directly relevant to dried inflorescence intended for pharmacy dispensing.
Frequently worth it for template alignment (batch records, deviation forms, change control). Poor first impressions cost more than early template fees.
Search combinations like EU GMP Annex 7 herbal, medical cannabis GMP drying, batch manufacturing record herbal—and always verify with professional regulatory counsel for binding decisions.
Time-segregated flows or physical barriers plus personnel badging. Never overlap dirty outdoor harvest receiving with open primary packaging without engineering controls.
Expect solvent handling, explosion-proof electrical zones, and residual solvent validation. Extract GMP is not a light add-on to flower rooms.
Yes, if technical transfer and batch ownership are clear. You still need traceability and starting material specs that survive transfer.
Follow customer contract and Thai retention rules—often many years beyond last shipment. Digital imaging must be validated if it replaces paper.
Define in change control SOP with examples: new supplier of primary packaging = major; typo fix on non-critical label artwork may be minor with QP notification rules per agreement.
Yes. Use English checklists, trace batch folders blind, and score findings by risk. Internal leniency trains bad habits.
